ConductScience.org, home

Paper40123005

Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.

Minakata D and 23 others. Bone Marrow Transplant, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Papers, record 40123005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40123005

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.
PubMed
Journal
Bone Marrow Transplant
PubMed
Year
2025
PubMed
Publication types
Letter
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-03
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Minakata DDaisukehttps://orcid.org/0000-0001-7529-5585
2Fujiwara SIShin-Ichirohttps://orcid.org/0000-0002-4523-2994
3Honda SSeina
4Tominaga RRyutarohttps://orcid.org/0000-0003-2113-7631
5Yokoyama DDaizo
6Noguchi AAtsuto
7Furuki SShuka
8Koyama SShunsuke
9Murahashi RRui
10Nakashima HHirotomo
11Hyodo KKazuki
12Kawaguchi SIShin-Ichiro
13Ikeda TTakashi
14Toda YYumiko
15Mashima KKiyomi
16Umino KKento
17Ueda MMasuzu
18Ashizawa MMasahiro
19Yamamoto CChihirohttps://orcid.org/0000-0002-5333-8414
20Hatano KKaoru

Source PubMed

See all 24 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112634731Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.Bone Marrow Transplant2003https://conductscience.org/library/papers/12634731PubMed
228249894Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.Clin Cancer Res2017https://conductscience.org/library/papers/28249894PubMed
37581119Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.Bone Marrow Transplant1995https://conductscience.org/library/papers/7581119PubMed
411436099Engraftment syndrome following hematopoietic stem cell transplantation.Bone Marrow Transplant2001https://conductscience.org/library/papers/11436099PubMed
523806770Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.Biol Blood Marrow Transplant2013https://conductscience.org/library/papers/23806770PubMed
632325490Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.Blood2020https://conductscience.org/library/papers/32325490PubMed
731171419
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet2019https://conductscience.org/library/papers/31171419PubMed
823208313Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Bone Marrow Transplant2013https://conductscience.org/library/papers/23208313PubMed
938084760Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med2024https://conductscience.org/library/papers/38084760PubMed
1026327628Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach.Biol Blood Marrow Transplant2015https://conductscience.org/library/papers/26327628PubMed
1130778767Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.Int J Hematol2019https://conductscience.org/library/papers/30778767PubMed
1227222480Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.Blood2016https://conductscience.org/library/papers/27222480PubMed

Download CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40123005

GET https://conductscience.org/api/papers/v1/40123005/authors?page=2